Research and Markets: Malignant Glioma - Pipeline Review, H1 2013 Reviews Key Players Involved in the Therapeutic Development
Research and Markets (http://www.researchandmarkets.com/research/llf5tr/malignant_glioma) has announced the addition of the "Malignant Glioma - Pipeline Review, H1 2013" report to their offering.
Global Markets Direct's, 'Malignant Glioma - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Malignant Glioma, complete with latest updates, and special features on late-stage and discontinued projects. Malignant Glioma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
- A snapshot of the global therapeutic scenario for Malignant Glioma.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Malignant Glioma pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
- Boehringer Ingelheim GmbH
- F. Hoffmann-La Roche Ltd.
- Amgen Inc.
- AstraZeneca PLC
- Eli Lilly and Company
- Eisai Co., Ltd.
- Oncolytics Biotech Inc.
- Cytomedix, Inc.
- Nerviano Medical Sciences S.r.l.
- BioNumerik Pharmaceuticals, Inc.
- Biovista Inc.
- EirGen Pharma Ltd.
For more information visit http://www.researchandmarkets.com/research/llf5tr/malignant_glioma
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.